Patents by Inventor Dominic Schiller

Dominic Schiller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20210059959
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Application
    Filed: April 10, 2020
    Publication date: March 4, 2021
    Applicant: GW Pharma Limited
    Inventors: Philip ROBSON, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Use of cannabinoids in the treatment of mental disorders
    Patent number: 10653641
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 19, 2020
    Assignee: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20180344660
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 6, 2018
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20170007551
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
    Type: Application
    Filed: June 16, 2016
    Publication date: January 12, 2017
    Applicant: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Emma Cheetham, Orrin Devinsky, Dominic Schiller
  • USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20150359756
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: June 17, 2015
    Publication date: December 17, 2015
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Emma Cheetham, Orrin Devinsky, Dominic Schiller